Global Biosimilars Market size: NA vs Europe Comparison (2024–2032)

Free

in USD Million

Regulatory Advancements Boost to North America Biosimilars Market Expansion (2024–2032)

Published by MMR Statistics Reserch Team, November 2025

The global biosimilars landscape demonstrated strong regional progression, with North America and Europe remaining the two most influential markets through 2032. North America was valued at USD 13,991.97 million in 2024 and is projected to reach USD 34,335.12 million by 2032, driven by expanding biosimilar approvals, robust commercialization pathways, and increasing uptake across oncology, autoimmune, and chronic disease therapies. Europe was valued at USD 11,017.35 million in 2024 and is projected to grow to USD 28,298.77 million by 2032, supported by strong regulatory harmonization, widespread clinical adoption, and active tender-based procurement systems. While North America maintains the largest market position, Europe’s sustained growth reflects deeper clinical integration and competitive pricing frameworks. Together, these two regions continue to anchor global biosimilars expansion through rising demand and policy-driven market modernization.

OTHER STATISTICS ON TOPIC

Biosimilars

More statistics on Biosimilars

Download

Information

Unit

in USD Million

Region

Global

Time Period

2024-2032

Source Name

Maximize Market Research Pvt. Ltd

Source Link

http://www.maximizemarketresearch.com

Publisher Name

Maximize Market Research Pvt. Ltd

Publisher Link

http://www.maximizemarketresearch.com

Related reports

Market Research Reports on Biosimilars

Explore published research tied to this statistic's topic. Open the featured edition or jump into another region without leaving the page.

Open featured report

Subscriptions

Stay ahead of Biosimilars with tailored access

Sample free-tier statistics or unlock premium coverage for this topic with team-friendly usage rights.

Discover

Try free-tier statistics before committing to a plan.

Start for Free

Professional

Unlock premium coverage across this topic with analyst support.

Select Plan

Contact our team

Need a bespoke deep-dive on Biosimilars?

Tell us about your KPIs and coverage priorities. We can tailor a briefing, share methodology notes, or build a custom dataset that complements the reports and statistics you are browsing.

Talk with an analyst